Wells Fargo’s Artelo Biosciences ARTL Stock Holding History

Wells Fargo’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$37	–	6901
2024 Q1	$37	Hold	1	–	–	﹤0.01%	6909
2023 Q4	$31	Hold	1	–	–	﹤0.01%	7060
2023 Q3	$31	Hold	1	–	–	﹤0.01%	7050
2023 Q2	$38	Hold	1	–	–	﹤0.01%	7124
2023 Q1	$42	Hold	1	–	–	﹤0.01%	7155
2022 Q4	$52	Sell	1 -2	-67%	-$104	﹤0.01%	6995
2022 Q3	$0	Buy	3 +2	+200%	+$161	﹤0.01%	6630
2022 Q2	$0	Hold	1	–	–	﹤0.01%	6770
2022 Q1	$0	Hold	1	–	–	﹤0.01%	7017
2021 Q4	$0	Hold	1	–	–	﹤0.01%	7190
2021 Q3	$0	Buy	+1	New	+$254	﹤0.01%	6942
2021 Q2	–	Hold	0	–	–	–	6881
2021 Q1	–	Hold	0	–	–	–	6868
2020 Q4	–	Hold	0	–	–	–	6467
2020 Q3	–	Hold	0	–	–	–	6310
2020 Q2	–	Hold	0	–	–	–	6265
2020 Q1	–	Hold	0	–	–	–	6173

Other funds holding ARTL

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RIL

Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return

Wells Fargo's ARTL Position: Q2 2024 in Review

Wells Fargo sold out of Artelo Biosciences (ARTL) in Q2 2024, closing a stake of 1 share — an estimated $37 sold.

Wells Fargo first reported a position in ARTL in Q3 2021 and held it in 11 quarters. The position peaked at $52 in Q4 2022. 5 funds tracked by Wall St. Rank hold ARTL as of Q2 2024.

Wells Fargo reported no remaining Artelo Biosciences position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 1 Artelo Biosciences share in Q2 2024, an estimated $37.
Wells Fargo first reported a position in Artelo Biosciences in Q3 2021 and held it in 11 quarters.
Wells Fargo's Artelo Biosciences position peaked at $52 in Q4 2022.
5 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.